BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc. filed an S-1 registration statement with the U.S. Securities and Exchange Commission on August 29, 2025, initiating the public offering process for the blank check company that will trade under the ticker HLXB. The SPAC, bearing the name of clinical-stage biopharmaceutical firm BridgeBio Pharma, is targeting the oncology and life sciences sector with an aim to identify a merger candidate in cancer therapeutics. As of the filing date, the company had not yet announced a definitive business combination target. Sign up for full data on SpacDesk to track HLXB's deal status, filings, and pipeline activity in real time.